Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Moleculin Biotech, Inc. - Common Stock
(NQ:
MBRX
)
0.3850
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Moleculin Biotech, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
What's going on in today's session
↗
February 14, 2025
Here are the top movers in Friday's session, showcasing the stocks with significant price changes.
Via
Chartmill
Top movers in Friday's pre-market session
↗
February 14, 2025
Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via
Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
February 14, 2025
Via
Benzinga
US Stocks Set For A Volatile Start: Analyst Dismisses Chances Of 20%+ S&P 500 Gain For Third Year In A Row, But Says 'Investors Should Be Optimistic'
↗
February 14, 2025
U.S. stock futures traded close to the flatline on Friday after Tuesday's rally. Futures of all four benchmark indices were slightly lower.
Via
Benzinga
Topics
Stocks
Insights Ahead: Moleculin Biotech's Quarterly Earnings
↗
November 07, 2024
Via
Benzinga
Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
April 25, 2024
Via
ACCESSWIRE
Why Airbnb Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
↗
February 14, 2025
Via
Benzinga
Keep an eye on the top gainers and losers in Thursday's session.
↗
February 13, 2025
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
Via
Chartmill
The trading volume of these stocks is deviating from the norm in today's session.
↗
February 13, 2025
The trading volume of these stocks is deviating from the norm in today's session.
Via
Chartmill
Which stocks are moving on Thursday?
↗
February 13, 2025
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.
Via
Chartmill
MBRX Stock Earnings: Moleculin Biotech Reported Results for Q4 2023
↗
March 22, 2024
Moleculin Biotech just reported results for the fourth quarter of 2023.
Via
InvestorPlace
A Preview Of Moleculin Biotech's Earnings
↗
March 21, 2024
Via
Benzinga
Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?
↗
February 13, 2025
Moleculin Biotech received FDA guidance reducing its Phase 3 trial size for Annamycin in AML. First unblinding is expected in late 2025, with another in 2026.
Via
Benzinga
Thursday's session: gap up and gap down stocks
↗
February 13, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps.
Via
Chartmill
Unusual volume stocks in Wednesday's session
↗
February 12, 2025
On Wednesday, there are stocks with unusual volume. Let's take a look.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
February 06, 2025
Via
Benzinga
Why Coherent Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
↗
February 06, 2025
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
December 11, 2024
Via
Benzinga
What's Going On With Moleculin Biotech Shares Wednesday?
↗
December 11, 2024
Moleculin Biotech shares are trading higher on Wednesday after the company announced the online publication of preclinical data for its Annamycin Venetoclax Resistant AML model.
Via
Benzinga
MBRX Stock Earnings: Moleculin Biotech Beats EPS for Q2 2024
↗
August 14, 2024
MBRX stock results show that Moleculin Biotech beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
June 14, 2024
Via
Benzinga
MBRX Stock Earnings: Moleculin Biotech Beats EPS for Q1 2024
↗
May 10, 2024
MBRX stock results show that Moleculin Biotech beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
April 26, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
April 08, 2024
Via
Benzinga
Earnings Scheduled For March 22, 2024
↗
March 22, 2024
Companies Reporting Before The Bell • Agile Therapeutics (NASDAQ:AGRX) is likely to report quarterly loss at $0.54 per share on revenue of $9.20 million.
Via
Benzinga
Micron, Signet Jewelers And 3 Stocks To Watch Heading Into Wednesday
↗
March 20, 2024
With U.S. stock futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
March 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
March 18, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
March 04, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
↗
January 24, 2024
It's time to dive into the biggest pre-market stock movers on Tuesday with a breakdown of all the latest news affecting shares this morning.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
